Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Dec 5;68(12):e0123224.
doi: 10.1128/aac.01232-24. Epub 2024 Nov 13.

Targeted antimicrobial regimens for Gram-negative prosthetic joint infections: a prospective multicenter study

Jaap L J Hanssen  1 , Robert J P van der Wal  2 , Rachid Mahdad  3 , Stefan Keizer  4 , Nathalie M Delfos  5 , Joris C T van der Lugt  6 , Karin Ellen Veldkamp  7 , Peter A Nolte  8   9 , Masja Leendertse  10 , Luc B S Gelinck  11 , Femke P N Mollema  11 , Emile F Schippers  1   12 , Hanke G Wattel-Louis  13 , Rob G H H Nelissen  2 , Henk Scheper  1 , Mark G J de Boer  1   14
Affiliations
Multicenter Study

Targeted antimicrobial regimens for Gram-negative prosthetic joint infections: a prospective multicenter study

Jaap L J Hanssen et al. Antimicrob Agents Chemother. .

Abstract

Fluoroquinolones (FQs) are considered the most effective antimicrobial treatment for Gram-negative prosthetic joint infection (GN-PJI). Alternatives are needed due to increasing FQ resistance and side effects. We aimed to compare different targeted antimicrobial strategies for GN-PJI managed by debridement, antibiotics, and implant retention (DAIR) or one-stage revision surgery (1SR) and to review the literature of oral treatment options for GN-PJI. In this prospective, multicenter, registry-based study, all consecutive patients with a PJI caused by a Gram-negative microorganism (including mixed infections with Gram-positive microorganisms), managed with DAIR or 1SR from 2015 to 2020, were included. Minimum follow-up was 1 year. Patients underwent targeted therapy with oral FQ, oral cotrimoxazole, or intravenous or oral β-lactams. Survival analysis was performed with use of Kaplan-Meier and Cox proportional hazards models to identify factors potentially associated with treatment failure. Seventy-four patients who received either FQ (n = 47, 64%), cotrimoxazole (n = 13, 18%), or β-lactams (n = 14, 18%) were included. Surgical strategy consisted of DAIR (n = 72) or 1SR (n = 2). Median follow-up was 449 days (interquartile range 89-738 days). Failure free survival did not differ between the FQ (72%) and cotrimoxazole (92%) groups (log rank, P = 0.13). This outcome did not change when excluding all pseudomonal PJI in the FQ group. Cotrimoxazole is a potential effective targeted antimicrobial therapy for patients with GN-PJI. A randomized controlled trial is needed to confirm the findings of this study.

Keywords: Gram-negative PJI; antimicrobial treatment; prosthetic joint infections; total hip; total knee.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig 1
Fig 1
Inclusion flowchart. DAIR, debridement, antibiotics, and implant retention; PJI, prosthetic joint infection.
Fig 2
Fig 2
Survival analysis for Gram-negative prosthetic joint infections treated with DAIR or one-stage revision, related to antimicrobial treatment strategy.
See this image and copyright information in PMC

References

    1. Benito N, Mur I, Ribera A, Soriano A, Rodríguez-Pardo D, Sorlí L, Cobo J, Fernández-Sampedro M, Del Toro MD, Guío L, et al. . 2019. The different microbial etiology of prosthetic joint infections according to route of acquisition and time after prosthesis implantation, including the role of multidrug-resistant organisms. J Clin Med 8:673. doi:10.3390/jcm8050673 - DOI - PMC - PubMed
    1. Tai DBG, Patel R, Abdel MP, Berbari EF, Tande AJ. 2022. Microbiology of hip and knee periprosthetic joint infections: a database study. Clin Microbiol Infect 28:255–259. doi:10.1016/j.cmi.2021.06.006 - DOI - PMC - PubMed
    1. Ariza J, Cobo J, Baraia-Etxaburu J, Benito N, Bori G, Cabo J, Corona P, Esteban J, Horcajada JP, Lora-Tamayo J, Murillo O, Palomino J, Parra J, Pigrau C, Del Pozo JL, Riera M, Rodríguez D, Sánchez-Somolinos M, Soriano A, Del Toro MD, de la Torre B, Spanish Network for the Study of Infectious Diseases and the Sociedad Española de Enfermedades Infecciosas, Microbiología Clínica (SEIMC) . 2017. Executive summary of management of prosthetic joint infections. Clinical practice guidelines by the Spanish society of infectious diseases and clinical microbiology (SEIMC). Enferm Infecc Microbiol Clin 35:189–195. doi:10.1016/j.eimc.2016.08.012 - DOI - PubMed
    1. Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, Rao N, Hanssen A, Wilson WR, Infectious Diseases Society of America . 2013. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 56:e1–e25. doi:10.1093/cid/cis803 - DOI - PubMed
    1. Zijlstra WP, Ploegmakers JJW, Kampinga GA, Toren-Wielema ML, Ettema HB, Knobben BAS, Jutte PC, Wouthuyzen-Bakker M, Northern Infection Network for Joint Arthroplasty (NINJA) . 2022. A protocol for periprosthetic joint infections from the Northern Infection Network for Joint Arthroplasty (NINJA) in the Netherlands. Arthroplasty 4:19. doi:10.1186/s42836-022-00116-9 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources